133 related articles for article (PubMed ID: 8165852)
21. A safety and immunogenicity comparison of 12 acellular pertussis vaccines and one whole-cell pertussis vaccine given as a fourth dose in 15- to 20-month-old children.
Pichichero ME; Deloria MA; Rennels MB; Anderson EL; Edwards KM; Decker MD; Englund JA; Steinhoff MC; Deforest A; Meade BD
Pediatrics; 1997 Nov; 100(5):772-88. PubMed ID: 9346976
[TBL] [Abstract][Full Text] [Related]
22. Reactogenicity and immunogenicity of reduced antigen content diphtheria-tetanus-acellular pertussis vaccines as a booster in 4-7-year-old children primed with diphtheria-tetanus-whole cell pertussis vaccine before 2 years of age.
Dagan R; Igbaria K; Piglansky L; Van Brusteghem F; Melot V; Kaufhold A
Vaccine; 1999 Jun; 17(20-21):2620-7. PubMed ID: 10418911
[TBL] [Abstract][Full Text] [Related]
23. A controlled trial of two acellular vaccines and one whole-cell vaccine against pertussis. Progetto Pertosse Working Group.
Greco D; Salmaso S; Mastrantonio P; Giuliano M; Tozzi AE; Anemona A; Ciofi degli Atti ML; Giammanco A; Panei P; Blackwelder WC; Klein DL; Wassilak SG
N Engl J Med; 1996 Feb; 334(6):341-8. PubMed ID: 8538704
[TBL] [Abstract][Full Text] [Related]
24. Assessment of the immunogenicity and reactogenicity of a quadrivalent diphtheria, tetanus, acellular pertussis and hepatitis B (DTPa-HBV) vaccine administered in a single injection with Haemophilus influenzae type b conjugate vaccine, to infants at 2, 4 and 6 months of age.
Arístegui J; Dal-Ré R; Garrote E; González A; Arrate JP; Pérez A
Vaccine; 1998 Dec; 16(20):1976-81. PubMed ID: 9796053
[TBL] [Abstract][Full Text] [Related]
25. Effect of schedule on reactogenicity and antibody persistence of acellular and whole-cell pertussis vaccines: value of laboratory tests as predictors of clinical performance.
Miller E; Ashworth LA; Redhead K; Thornton C; Waight PA; Coleman T
Vaccine; 1997 Jan; 15(1):51-60. PubMed ID: 9041666
[TBL] [Abstract][Full Text] [Related]
26. The effect of maternal antibody on the serologic response and the incidence of adverse reactions after primary immunization with acellular and whole-cell pertussis vaccines combined with diphtheria and tetanus toxoids.
Englund JA; Anderson EL; Reed GF; Decker MD; Edwards KM; Pichichero ME; Steinhoff MC; Rennels MB; Deforest A; Meade BD
Pediatrics; 1995 Sep; 96(3 Pt 2):580-4. PubMed ID: 7659480
[TBL] [Abstract][Full Text] [Related]
27. Immunogenicity and protective efficacy of neonatal vaccination against Bordetella pertussis in a murine model: evidence for early control of pertussis.
Roduit C; Bozzotti P; Mielcarek N; Lambert PH; del Giudice G; Locht C; Siegrist CA
Infect Immun; 2002 Jul; 70(7):3521-8. PubMed ID: 12065491
[TBL] [Abstract][Full Text] [Related]
28. Effect of gender, race, and parental education on immunogenicity and reported reactogenicity of acellular and whole-cell pertussis vaccines.
Christy C; Pichichero ME; Reed GF; Decker MD; Anderson EL; Rennels MB; Englund JA; Edwards KM; Steinhoff MC
Pediatrics; 1995 Sep; 96(3 Pt 2):584-7. PubMed ID: 7659481
[TBL] [Abstract][Full Text] [Related]
29. Does whole-cell pertussis vaccine protect black South African infants? Assessment of post-vaccination events and antibody responses to pertussis toxin, filamentous haemagglutinin and agglutinogens 2 and 3.
Ramkissoon A; Coovadia HM; Loening WE; Ndlovana M
S Afr Med J; 1991 Jun; 79(11):645-9. PubMed ID: 1675492
[TBL] [Abstract][Full Text] [Related]
30. Reactogenicity and immunogenicity of reduced antigen content diphtheria-tetanus-acellular pertussis vaccine (dTpa) administered as a booster to 4-6 year-old children primed with four doses of whole-cell pertussis vaccine.
Kosuwon P; Warachit B; Hutagalung Y; Borkird T; Kosalaraksa P; Bock HL; Poovorawan Y
Vaccine; 2003 Oct; 21(27-30):4194-200. PubMed ID: 14505898
[TBL] [Abstract][Full Text] [Related]
31. Effect of priming with diphtheria and tetanus toxoids combined with whole-cell pertussis vaccine or with acellular pertussis vaccine on the safety and immunogenicity of a booster dose of an acellular pertussis vaccine containing a genetically inactivated pertussis toxin in fifteen- to twenty-one-month-old children. Italian Multicenter Group for the Study of Recombinant Acellular Pertussis Vaccine.
Podda A; Bona G; Canciani G; Pistilli AM; Contu B; Furlan R; Meloni T; Stramare D; Titone L; Rappuoli R
J Pediatr; 1995 Aug; 127(2):238-43. PubMed ID: 7636648
[TBL] [Abstract][Full Text] [Related]
32. Comparison of the safety and immunogenicity of acellular (BIKEN) and whole-cell pertussis vaccines in 15- to 20-month-old children.
Marcinak JF; Ward M; Frank AL; Boyer KM; Froeschle JE; Hosbach PH
Am J Dis Child; 1993 Mar; 147(3):290-4. PubMed ID: 8438810
[TBL] [Abstract][Full Text] [Related]
33. Safety and immunogenicity of a combined Tetanus, Diphtheria, recombinant acellular Pertussis vaccine (TdaP) in healthy Thai adults.
Sirivichayakul C; Chanthavanich P; Limkittikul K; Siegrist CA; Wijagkanalan W; Chinwangso P; Petre J; Hong Thai P; Chauhan M; Viviani S
Hum Vaccin Immunother; 2017 Jan; 13(1):136-143. PubMed ID: 27686283
[TBL] [Abstract][Full Text] [Related]
34. Acellular pertussis vaccines in infants: evaluation of single component and two-component products.
Anderson EL; Mink CM; Berlin BS; Shih CN; Tung FF; Belshe RB
Vaccine; 1994 Jan; 12(1):28-31. PubMed ID: 8303937
[TBL] [Abstract][Full Text] [Related]
35. Immunogenicity of a five-component acellular pertussis vaccine in infants and young children.
Halperin SA; Barreto L; Friesen B; Meekison W
Arch Pediatr Adolesc Med; 1994 May; 148(5):495-502. PubMed ID: 7910089
[TBL] [Abstract][Full Text] [Related]
36. Serological responses to infection with B. pertussis.
Giammanco A; Taormina S; Genovese M; Mangiaracina G; Giammanco G; Chiarini A
Dev Biol Stand; 1997; 89():213-20. PubMed ID: 9272353
[TBL] [Abstract][Full Text] [Related]
37. Serum antibodies to diphtheria-tetanus-pertussis vaccine components in Argentine children.
Pasetti M; Eriksson P; Ferrero F; Manghi M
Infection; 1997; 25(6):339-45. PubMed ID: 9427051
[TBL] [Abstract][Full Text] [Related]
38. Diphtheria-tetanus-acellular pertussis vaccine adsorbed (Triacelluvax; DTaP3-CB): a review of its use in the prevention of Bordetella pertussis infection.
Matheson AJ; Goa KL
Paediatr Drugs; 2000; 2(2):139-59. PubMed ID: 10937466
[TBL] [Abstract][Full Text] [Related]
39. Clinical reactions and immunogenicity of the BIKEN acellular diphtheria and tetanus toxoids and pertussis vaccine in 4- through 6-year-old US children.
Bernstein HH; Rothstein EP; Pichichero ME; Francis AB; Kovel AJ; Disney FA; Green JL; Marsocci SM; Lynd AM; Wood GC
Am J Dis Child; 1992 May; 146(5):556-9. PubMed ID: 1621656
[TBL] [Abstract][Full Text] [Related]
40. Two primary doses of diphtheria-tetanus-acellular pertussis vaccine induce immunological responses to Bordetella pertussis as strong as those induced by three primary doses.
Tomoda T; Ogura H; Kurashige T
Vaccine; 1997 Dec; 15(17-18):1955-8. PubMed ID: 9413107
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
